Sunday , December 5 2021

How the two companies progressed in the race against the Covid vaccine



[ad_1]

In mid-March, when the novel coronavirus was gaining strength in the United States, Albert Bourla, CEO of Pfizer Inc., called on top vaccine scientists and set a clear mission:

“He basically said, ‘Your authority is to make this vaccine. If you need the resources, you will come and ask for them and you will get them,” said Philip Dormitzer, the chief vaccine scientist against the virus. Reuters.

The task was inspiring and daunting. He helped researchers deal with something that had never been done before: designing a vaccine to stop a pandemic in less than a year.

“He didn’t want to focus on potential obstacles that we might have wanted, but he said it’s much better to try to do something that seemed impossible, and despite not being successful, you still (will) do something great,” Dormitzer said, noting the vaccine that new developments could be around $ 1 billion (RM 4.125 billion).

Following this, a full-scale effort was made under strict conditions to block coronavirus, borrowing elements from ongoing influenza and cancer research, according to Reuters interviews with half a dozen scientists critical of the vaccination program run by Pfizer and its German partner BioNTech SE …

[ad_2]
Source link